Illumina – Talk Bio

Illumina and Tempus look beyond cancer in new AI-driven genomics deal

1 week ago talkbio0Tagged Artificial Intelligence, Cardiology discipline, Genetic Profile, Genomics, High-Throughput Nucleotide Sequencing, Illumina, Immunology, Malignant Neoplasms, Market, Neurology speciality, Partnership

Illumina, Genomics, Partnership, High-Throughput Nucleotide Sequencing, Malignant Neoplasms, Artificial Intelligence, Cardiology discipline, Neurology speciality, Immunology, Genetic Profile, Artificial Intelligence, Market

Illumina Reshapes Board: Former FDA Chief Takes Chair, Activist Investor Joins

4 weeks ago talkbio0Tagged board changes, Genomics, Illumina, Keith, Meister, Scott Gottlieb, shareholder

Illumina, Scott Gottlieb, Keith Meister, board changes, genomics, shareholder value

Illumina Announces Layoffs as Incyte Forges AI Partnership for Drug Discovery

2 months ago talkbio0Tagged Aortic Valve Insufficiency, Drug Discovery, FOXD3 gene, Gemini of Coiled Bodies, Illumina, Incyte, Partnership

Illumina, layoffs, Incyte, Genesis Therapeutics, AI partnership, drug discovery, GEMS platform, small molecule therapeutics

Illumina’s Double-Edged Sword: Navigating US-China Trade Tensions

3 months ago talkbio0Tagged BIOSECURE, China, DNA Sequence, Entity, Illumina, Industry, Tension, TNFRSF19 gene, unreliable

Illumina, China, tariffs, trade tensions, DNA sequencing, unreliable entity list, biotech industry, BIOSECURE Act

Truveta Genome Project: A Historic 10M Genome Sequencing Initiative Backed by Regeneron, Illumina, and Leading Health Systems

3 months ago talkbio0Tagged Drug Discovery, genetic sequencing, genome sequencing, Genotype, healthcare analytics, Illumina, phenotypic, Precision Medicine, Regeneron, Truveta

Truveta Genome Project, 10M genome sequencing, Regeneron, Illumina, genetic sequencing, genotypic and phenotypic data, healthcare analytics, drug discovery, personalized medicine.

Pleno Secures $25M Funding for Commercial Launch, Appoints New CEO from Illumina

4 months ago talkbio0Tagged CEO, commercial, Illumina, launch, Multiomics, Pleno

Pleno, multiomics, funding, commercial launch, new CEO, Illumina

Illumina Introduces MiSeq i100 Series: Simplifying Next-Generation Sequencing with Push-Button Workflows

7 months ago talkbio0Tagged Benchtop DNA Sequencer, DNA Sequence, Genomics, High-Throughput Nucleotide Sequencing, Illumina, MiSeq, Push-Button, Workflow

Illumina, MiSeq i100 Series, Benchtop DNA Sequencer, Push-Button Workflows, Next-Generation Sequencing (NGS), Genomics, DNA Sequencing

EU High Court Rules in Favor of Illumina in Grail Acquisition Appeal

8 months ago talkbio0Tagged Acquisition (action), Antitrust, European (ethnic group), Grail, Illumina, Liquid Biopsy, Litigation

Illumina, Grail, European Court of Justice, Acquisition, Antitrust Litigation, Liquid Biopsy

FDA Approves Illumina’s TruSight Oncology Comprehensive Test for Pan-Cancer Companion Diagnostics

8 months ago talkbio0Tagged Approved, cellular targeting, Comprehensive, Diagnostics, Gene Fusion, Illumina, Neoplasms, NTRK, pan-cancer, Pet Animal, Precision - temporal, RET protein, human, TruSight Oncology, United States Food and Drug Administration

FDA approval, Illumina, TruSight Oncology Comprehensive, pan-cancer, companion diagnostics, NTRK gene fusions, RET fusion-positive NSCLC, targeted therapies, precision oncology.

Grail Lays Off About 350 Employees, Puts Brakes on New Hires

8 months ago talkbio0Tagged cost-cutting measures, Detection, Galleri test, Grail, Illumina, Malignant Neoplasms, restructuring

Grail, layoffs, restructuring, biotech, cancer detection, Galleri test, Illumina, workforce reduction, cost-cutting measures